

Efficient Biomimetic-Type Synthesis of the Benzo[*a*]naphthacenequinone Antibiotics G-2A and G-2N


Karsten Krohn^{*[a]} and Sven Bernhard^[a]

Keywords: Antibiotics / Biomimetic-type synthesis / Polyketides / Quinones / Aldol reaction

Trioxo ester **15** was prepared by attachment of two vicinal C-4 and C-6 ketide side chains on the anthraquinone core (**6b**). Mild base treatment of **15** initiated successive aldol condensations to produce the benzo[*a*]naphthacenequinone

16 regioselectively in one operation. Deprotection of **16** afforded the antibiotic G-2A (**1**) and decarboxylation of **1** lead to G-2N (**2**).

The structurally most simple natural products with the benzo[*a*]naphthacenequinone skeleton named G-2A (**1**) and G-2N (**2**) were isolated in 1984 by Gerber and Lechevalier from the actinomycete *Frankia* sp. G2.^[1] The initially proposed structures were revised later by Hauser and Carin-gal^[2] by comparison of synthetic material with the original structures. In the meantime, the number of known antibiotics of this class has grown to over twenty compounds. Whereas G-2A (**1**) and G-2N (**2**)^[1] and also derivatives of madurahydroxylactone (**3**)^[3] have antibacterial activity, the related *O*-glycosidic pradimicins^{[4][5]} and benanomicins^{[6][7]} possess remarkable in vivo antifungal properties.^[8] There is an urgent need for new antifungal agents because mycoses pose a severe problem in current therapy of immunodeficient patients.^[9]



A previous synthesis of G-2N (**2**)^[10] and approaches to the benanomicin family^[11–13] relied on the Diels–Alder reaction in the construction of the benzo[*a*]naphthacenequinone skeleton, whereas an intramolecular Stille coupling was the key step in the synthesis of G-2A (**1**) and G-2N (**2**) by Kelly et al.^[14] We now report on an efficient biomimetic-type total synthesis of the benzo[*a*]naphthacenequinone pigments **1** and **2**, in which the problems of aryl–aryl coupling and the generation of the specific acetogenic substitution pattern of the polyketide natural products are solved simultaneously in a single step.

The synthetic strategy anticipated the attachment of two short ketide chains on vicinal positions on an anthraqui-

none core in an extension of an earlier approach to the aromatic angucycline antibiotics.^[15] This approach reduces the large number of possible unwanted aldol reactions of highly reactive polyketide intermediates. In addition, the careful choice of protecting groups is also a requirement for selective cyclizations, as has been shown by the pioneering work of Harris et al.^[16]

The required anthraquinone, **6b**, that allowed the later attachment of the ketide side chains was prepared by Diels–Alder reaction of the chloronaphthoquinone (**4**)^[17] and the diene **5**.^[18] A 2:3 mixture of the phenol **6a** [30%, characterized as the bis(pivaloate) **6c**] and the ethyl ether **6b** (45%) was obtained after acid-catalyzed aromatization of the primary non-isolated Diels–Alder adduct (Scheme 1). Both products were, in principle, amenable to the anticipated further transformations, but the ethyl ether **6b** was taken for the subsequent steps because one of the phenolic hydroxy groups was already protected. After some experimentation with the corresponding acetates it was found that the pivaloyl esters were more stable, and the dipivaloate **7** was brominated with NBS at the benzylic position to form the monobromide **8** (93%). The sterically demanding pivaloate group effectively inhibited the formation of a dibromide which is normally the major product in the NBS bromination of unhindered benzylic positions. Alkylation of ethyl 5,5-diethylenedioxy-3-oxohexanecarboxylate (**9**)^[19] with the benzylic bromide **8** afforded the ester **10** without cleavage of the pivaloate protecting groups. Both the pivaloyl and the methyl esters were saponified by mild treatment of **10** with 1 N NaOH in ethanol. The resulting crude β-oxo acid was directly decarboxylated by heating to 100 °C to yield the phenolic ketone **11** in 89% total yield. NMR analysis revealed that the phenolic ketone **11** existed as a 2:1 mixture of the free ketone with the corresponding hemiacetal in CDCl₃ solution. This equilibrium did not prevent the subsequent selective reaction of the *non-chelated* phenolic group at C-3 to form the monotriflate **12** in 93% yield. In spite of steric hindrance, the triflate **12** reacted cleanly with the allylstannane **13**^[20] to yield the (*E*)-vinyl ether **14** (82%) with dichloro palladium 1,1-bis(diphenylphosphanyl)-ferrocene [PdCl₂(dppf)]^[21] as the catalyst. The vinyl ether **14** was cleaved quantitatively to the corresponding trioxo

[a] Fachbereich Chemie und Chemietechnik der Universität-GH Paderborn, Warburger Straße 100, D-33098 Paderborn, Germany
Fax: (internat.) + 49-(0)5251/603245
E-mail: kk@chemie.uni-paderborn.de

linearly condensed cyclization products. Finally, to complete the synthesis of the natural pigment, the diverse protecting groups of **16** were simultaneously cleaved by a short melt in $\text{AlCl}_3/\text{NaCl}$ at 150°C ^{[14][22]} to yield the natural product G-2A (**1**), which was further thermally decarboxylated to afford G-2N (**2**).^[14] The biomimetic-type synthesis of **1** can be extended easily to other members of the benzo[*a*]naphthacenequinone antibiotics such as the pradimicins and benanomycins.



General methods and instrumentation are given elsewhere.^[23]

1-Ethoxy-2-methyl-1,3-bis(trimethylsiloxy)buta-1,3-diene (5): A solution of ethyl 3-methylacetoacetate (5.00 g, 34.68 mmol) in dry *n*-hexane (40 mL) was treated under argon with triethylamine (4.21 g, 41.62 mmol). Trimethylsilyl chloride (4.14 g, 38.15 mmol) was then added dropwise and the suspension was stirred for 12 h. The mixture was filtered and the residue concentrated in vacuo to yield 6.75 g of crude ethyl 2-methyl-3-(trimethylsiloxy)but-2-enoate. This ester (2.00 g, 9.24 mmol) was then added dropwise to a solution of LDA (10.16 mmol) in dry THF (15 mL) at -78°C under argon, and after 30 min trimethylsilyl chloride (1.21 g, 11.09 mmol) was added slowly. The mixture was stirred for 1 h at 0°C and the solvent was evaporated under reduced pressure. *n*-Pentane (40 mL) was added to the suspension, the lithium chloride was removed by filtration and the filtrate was concentrated under reduced pressure to afford the diene **5**^[18] (2.45 g, 92%) as a 4:1 (*E*)/(*Z*) mixture that was used without further purification.

1,3,8-Trihydroxy-6-methoxy-2-methyl-9,10-anthraquinone (6a) and 1-Ethoxy-3,8-dihydroxy-6-methoxy-2-methyl-9,10-anthraquinone (6b): A mixture of naphthoquinone **4**^[17] (0.50 g, 2.10 mmol) and diene **5** (1.21 g, 4.20 mmol) in dry toluene (20 mL) was stirred under argon for 6 h at 20 °C. The solvent was evaporated under reduced pressure and the residue re-dissolved in a mixture of THF (20 mL) and conc. HCl (4 mL). The mixture was heated under reflux for 1 h, diluted with water (30 mL) and the remaining THF removed under reduced pressure. The 3:4.5 mixture of **6a**^[24] and **6b** (0.51 g, 75%) was isolated by filtration. The almost insoluble phenols **6a** and **6b** were characterized as the bis(pivalates) **6c** and **7**. – IR (KBr) of **6b**: $\tilde{\nu}$ = 3395 cm⁻¹ (OH), 2991, 2966, 2924 (CH), 1676 (C=O, quinone), 1631, 1604, 1571 (C=C, Ar); – ¹H NMR of **6b**: (200 MHz, [D₆]DMSO): δ = 1.41 (t, *J* = 6.8 Hz, 3 H, OCH₂CH₃), 2.12 (s, 3 H, CH₃), 3.88 (s, 3 H, OCH₃), 3.94 (q, *J* = 6.8 Hz, 2 H, OCH₂CH₃), 6.74 (d, *J*_{7,5} = 2.5 Hz, 1 H, 7-H), 7.01 (d, *J*_{5,7} = 2.5 Hz, 1 H, 5-H), 7.41 (s, 1 H, 4-H), 11.13 (s, 1 H, OH), 13.46 (s, 1 H, OH). – C₂₆H₂₈O₈ (468.50): calcd. C 66.66, H 6.02; found C 66.70, H 5.98.

3,8-Bis(2,2-dimethylpropionyloxy)-1-hydroxy-6-methoxy-2-methyl-9,10-anthraquinone (6c) and 3,8-Bis(2,2-dimethylpropionyloxy)-1-ethoxy-6-methoxy-2-methyl-9,10-anthraquinone (7): A suspension of the anthraquinones **6a** and **6b** (2.52 g, 8.42 mmol) and DMAP (0.10 g, 0.84 mmol) in a mixture of dry CH_2Cl_2 (80 mL) and dry pyridine (10 mL) was treated with pivaloyl chloride (6.09 g, 50.5 mmol). The mixture was stirred for 12 h at 20 °C, then poured into ice-cold 1 N HCl (100 mL) and extracted three times with CH_2Cl_2 (60 mL). The combined organic phases were washed successively with 1 N HCl (60 mL) and water (60 mL), dried (Na_2SO_4), filtered, and concentrated under reduced pressure. The residue was separated by chromatography on silica gel (CH_2Cl_2) to yield yellow

Scheme 1. a) 1. Toluene, 6 h, 20°C; 2. conc. HCl, THF (30% **6a**, 45% **6b**). – b) Me₃CCOCl, DMAP, pyridine (54%). – c) NBS, AIBN, CCl₄, reflux (93%). – d) Ethyl 5,5-diethylenedioxy-3-oxohexanecarboxylate (**9**), NaH (87%). – e) 1.1 N NaOH, EtOH; 2. 100°C (89%). – f) Tf₂O, 2,6-lutidine (93%). – g) Allylstannane **13**, PdCl₂(dppf), CuBr, dioxane, 3 h, 90°C (82%). – h) 1 N HCl, THF, reflux (95%). – i) K₂CO₃, *i*PrOH. – j) Me₃CCOCl, DMAP (74%). – k) AlCl₃/NaCl, 150°C, 5 min (87%). – l) Py/HCl, 160°C, 6 h (69%).^[14] – AIBN = azoisobutyronitrile, NBS = *N*-bromosuccinimide, DMAP = 4-(dimethylamino)pyridine, dppf = 1,1'-bis(diphenylphosphanyl)ferrocene

The spectral data of this dipivaloate **17** were in complete agreement with the expected benzo[*a*]naphthacenequinone skeleton. Interestingly, the presence of the ester group initiated the complete aromatization of the intermediate aldol products that could not even be detected by TLC. This is in contrast to experiments with similar precursors lacking this ester group, where the hydroaromatic primary aldol products can be isolated.^[15] Interestingly, ring A is aromatic in **all** natural products of related benzo[*a*]naphthacenequinone structures isolated to date with an ester group on this ring. It is further worth noting that only one cyclization mode to the *angularly* condensed system was realized under the mild basic conditions with the trioxo ester **15**, whereas partially protected analogues always also gave some of the

6c (1.46 g, 37%; m.p. 209°C) and **7** (2.26 g, 54%; m.p. 177°C) as faint yellow crystals.

Data for 6c: IR (KBr): $\tilde{\nu}$ = 3440 cm⁻¹ (OH), 2976, 2935 (CH), 1755 (C=O, ester), 1676 (C=O, quinone), 1630, 1601 (C=C, Ar). – UV (CH₂Cl₂): λ_{\max} (lg ϵ) = 228 nm (4.29), 271 (4.58), 414 (3.91). – ¹H NMR (200 MHz, CDCl₃): δ = 1.45 [s, 9 H, C(CH₃)₃], 1.49 [s, 9 H, C(CH₃)₃], 2.18 (s, 3 H, CH₃), 4.00 (s, 3 H, OCH₃), 6.83 (d, $J_{7,5}$ = 2.6 Hz, 1 H, 7-H), 7.44 (s, 1 H, 4-H), 7.72 (d, $J_{5,7}$ = 2.6 Hz, 1 H, 5-H), 13.38 (s, 1 H, OH). – ¹³C NMR (50 MHz, CDCl₃): δ = 9.64 (q, CH₃), 27.58 and 27.67 [q, C(CH₃)₃], 39.63 and 39.79 [s, C(CH₃)₃], 56.68 (q, OCH₃), 110.54 (d), 113.78 (d), 114.11 (s), 116.47 (d), 118.97 (s), 127.78 (s), 131.31 (s), 137.17 (s), 153.78 (s), 155.26 (s), 162.98 (s), 165.12 (s), 176.24 and 177.00 (s, CO₂Piv), 181.58 (s, C-10), 186.87 (s, C-9). – MS (EI/130°C): m/z (%) = 468 (59) [M⁺], 384 (33) [M⁺ – C₅H₈O], 300 (82) [M⁺ – 2 × C₅H₈O], 85 (38) [C₅H₉O⁺], 57 (100) [C₃H₅O⁺]. – HRMS: C₂₆H₂₈O₈: calcd. 468.178; found 468.178 ± 3 ppm.

Data for 7: IR (KBr): $\tilde{\nu}$ = 2976 cm⁻¹, 2935 (CH), 1749 (C=O, ester), 1673 (C=O, quinone), 1604 (C=C, Ar). – UV (CH₂Cl₂): λ_{\max} (lg ϵ) = 228 nm (4.25), 269 (4.65), 358 (3.82). – ¹H NMR (200 MHz, CDCl₃): δ = 1.44 [s, 9 H, C(CH₃)₃], 1.47 (t, J = 7.0 Hz, 3 H, OCH₂CH₃), 1.51 [s, 9 H, C(CH₃)₃], 2.22 (s, 3 H, CH₃), 3.97 (s, 3 H, OCH₃), 4.00 (q, J = 7.0 Hz, 2 H, OCH₂CH₃), 6.85 (d, $J_{7,5}$ = 2.7 Hz, 1 H, 7-H), 7.64 (d, $J_{5,7}$ = 2.7 Hz, 1 H, 5-H), 7.71 (s, 1 H, 4-H). – ¹³C NMR (50 MHz, CDCl₃): δ = 10.63 (q, CH₃), 16.12 (q, OCH₂CH₃), 27.60 [q, 2 × C(CH₃)₃], 39.60 and 39.79 [s, C(CH₃)₃], 56.57 (q, OCH₃), 70.94 (t, OCH₂CH₃), 109.23 (d, C-5), 116.53 and 117.03 (d, C-4 and C-7), 121.14 (s), 125.06 (s), 133.37 (s), 134.37 (s), 136.19 (s), 152.62 (s), 154.18 (s), 159.65 (s), 163.90 (s), 176.32 and 176.93 (s, CO₂Piv), 180.79 and 182.45 (s, C-9 and C-10). – MS (EI/200°C): m/z (%) = 496 (9) [M⁺], 411 (55) [M⁺ – C₅H₉O], 87 (100) [C₄H₇O₂⁺]. – HRMS: C₂₈H₃₂O₈: calcd. 496.209; found 496.209 ± 3 ppm. – C₂₈H₃₂O₈ (496.56): calcd. C 67.73, H 6.50; found C 67.68, H 6.56.

2-(Bromomethyl)-3,8-bis(2,2-dimethylpropionyloxy)-1-ethoxy-6-methoxy-9,10-anthraquinone (8): A suspension of **7** (1.10 g, 2.22 mmol), NBS (0.79 g, 4.44 mmol) and AIBN (50 mg) in CCl₄ (50 mL) was heated at reflux for 3 h. The mixture was filtered, the filtrate concentrated under reduced pressure, and a solution of the residue in CH₂Cl₂ (10 mL) was filtered through a short column of silica gel (CH₂Cl₂) to yield **8** (1.19 g, 93%) as a yellow solid; m.p. 169°C. – IR (KBr): $\tilde{\nu}$ = 2977 cm⁻¹ (CH), 1758 (C=O, ester), 1674 (C=O, quinone), 1603 (C=C, Ar). – UV (CH₂Cl₂): λ_{\max} (lg ϵ) = 229 nm (4.42), 277 (4.57), 354 (3.72). – ¹H NMR (200 MHz, CDCl₃): δ = 1.47 [s, 9 H, C(CH₃)₃], 1.50 [s, 9 H, C(CH₃)₃], 1.56 (t, J = 6.9 Hz, 3 H, OCH₂CH₃), 3.96 (s, 3 H, OCH₃), 4.15 (q, J = 6.9 Hz, 2 H, OCH₂CH₃), 4.56 (s, 2 H, CH₂Br), 6.84 (d, $J_{7,5}$ = 2.7 Hz, 1 H, 7-H), 7.62 (d, $J_{5,7}$ = 2.7 Hz, 1 H, 5-H), 7.80 (s, 1 H, 4-H). – ¹³C NMR (50 MHz, CDCl₃): δ = 16.14 (q, OCH₂CH₃), 20.62 (t, CH₂Br), 27.53 and 27.67 [q, C(CH₃)₃], 39.58 and 40.01 [s, C(CH₃)₃], 56.55 (q, OCH₃), 72.07 (t, OCH₂CH₃), 109.39 (d, C-5), 116.71 and 117.49 (d, C-4 and C-7), 120.97 (s), 124.94 (s), 132.60 (s), 135.34 (s), 135.97 (s), 152.67 (s), 154.01 (s), 159.76 (s), 164.08 (s), 175.82 and 176.79 (s, CO₂Piv), 180.32 and 182.05 (s, C-9 and C-10). – MS (EI/170°C): m/z (%) = 576 (11) [M⁺Br], 574 (10) [M⁺Br], 491 (29) [M⁺Br – C₅H₉O], 489 (28) [M⁺Br – C₅H₉O], 325 (25) [M⁺ – Br – 2 × C₅H₉O], 299 (20), 57 (100). – HRMS: C₂₈H₃₁O₈Br: calcd. 574.120; found 574.121 ± 3 ppm. – C₂₈H₃₁BrO₈ (575.45): calcd. C 58.44, H 5.43; found C 58.31, H 5.50.

Methyl 2-[3,8-Bis(2,2-dimethylpropionyloxy)-1-ethoxy-6-methoxy-9,10-dioxo-9,10-dihydroanthracene-2-ylmethyl]-4-(2-methyl[1,3]di-

oxolan-2-yl)-3-oxobutanoate (10): The sodium salt of methyl 5,5-diethylenedioxo-3-oxohexanoate (**9**)^[25] was prepared by stirring a solution of the ester **9** (1.02 g, 5.04 mmol) in dry THF (15 mL) with NaH (0.12 g, 5.04 mmol, 80%) under argon for 30 min at 20°C. This solution was added dropwise under argon at 20°C to a solution of the bromide **8** (1.45 g, 2.52 mmol) and tetrabutylammonium iodide (0.19 g, 0.50 mmol) in dry THF (25 mL). After 5 h of stirring, the mixture was poured into ice-cold 1 N HCl (100 mL) and extracted three times with CH₂Cl₂ (50 mL). The combined organic phases were dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The residue was purified by chromatography on silica gel (Et₂O/*n*-hexane, 6:4) to yield **10** (1.53 g, 87%) as a yellow oil. – IR (KBr): $\tilde{\nu}$ = 2979 cm⁻¹ (CH), 1756 (C=O, ester), 1675 (C=O, quinone). – UV (CH₂Cl₂): λ_{\max} (lg ϵ) = 227 nm (4.36), 273 (4.60), 356 (3.74). – ¹H NMR (200 MHz, CDCl₃): δ = 1.39 (s, 3 H, CH₃), 1.43 [s, 9 H, C(CH₃)₃], 1.50 [s, 9 H, C(CH₃)₃], 1.52 (t, J = 7.0 Hz, 3 H, OCH₂CH₃), 2.78 (d, J_{gem} = 14.3 Hz, 1 H, 4-H), 2.93 (d, J_{gem} = 14.3 Hz, 1 H, 4-H), 3.14–3.21 (m, 2 H, 1'-H), 3.66 (s, 3 H, CO₂CH₃), 3.90 (s, 3 H, OCH₃), 3.98–4.03 (m, 6 H, OCH₂CH₃, OCH₂CH₂O), 4.14 (pt, $J_{2,1''}$ = 7.9 Hz, $J_{2,1''}$ = 6.3 Hz, 1 H, 2-H), 6.86 (d, $J_{7',5'}$ = 2.5 Hz, 1 H, 7'-H), 7.66 (d, $J_{5',7'}$ = 2.5 Hz, 1 H, 5'-H), 7.71 (s, 1 H, 4'-H). – ¹³C NMR (50 MHz, CDCl₃): δ = 16.17 (q, OCH₂CH₃), 23.75 (t, C-1'), 24.69 (q, CH₃), 27.46 and 27.65 [q, C(CH₃)₃], 39.59 and 39.82 [s, C(CH₃)₃], 51.21 (t, C-4), 52.96 (q, CO₂CH₃), 56.58 (q, OCH₃), 58.59 (d, C-2), 64.88 and 65.02 (t, OCH₂CH₂O), 71.44 (t, OCH₂CH₃), 108.14 (s), 109.25 (d, C-5'), 116.67 and 117.43 (d C-4' and C-7'), 121.16 (s), 124.54 (s), 134.19 (s), 134.33 (s), 136.13 (s), 152.61 (s), 154.00 (s), 160.36 (s), 164.00 (s), 170.14 (s, CO₂CH₃), 176.48 and 176.77 (s, CO₂Piv), 180.63 and 182.33 (s, C-9' and C-10'), 201.20 (s, C-3). – MS (EI/170°C): m/z (%) = 696 (5) [M⁺], 611 (16) [M⁺ – C₅H₉O], 87 (100) [C₄H₇O₂⁺], 57 (43). – HRMS: C₃₇H₄₄O₁₃: calcd. 696.278; found 696.279 ± 3 ppm. – C₃₇H₄₄O₁₃ (696.75): calcd. C 63.78, H 6.37; found C 62.87, H 6.45.

1-Ethoxy-3,8-dihydroxy-6-methoxy-2-[4-(2-methyl[1,3]dioxolan-2-yl)-3-oxobutyl]-9,10-anthraquinone (11): A solution of the triester **10** (1.40 g, 2.01 mmol) in EtOH (60 mL) was stirred under argon with 1 N NaOH (60 mL) for 12 h. The mixture was acidified by addition of 1 N HCl (80 mL) and extracted three times with EtOAc (60 mL). The combined organic phases were washed with water (60 mL) and brine (60 mL), dried (Na₂SO₄), filtered, and concentrated under reduced pressure. The oily residue was heated for 10 min to 100°C and the crude ketone was purified by flash chromatography on silica gel (Et₂O/*n*-hexane, 80:20) to yield **11** (0.84 g, 89%) as an orange solid; m.p. 158°C. – The NMR spectra revealed an equilibrium of the ketone with the corresponding hemiacetal in CDCl₃ solution. – IR (KBr): $\tilde{\nu}$ = 3399 cm⁻¹ (OH), 2927 (CH), 1707, 1629, 1585 (C=C, Ar). – UV (CH₂Cl₂): λ_{\max} (lg ϵ) = 228 nm (4.34), 288 (4.57), 357 (3.65), 433 (3.89). – ¹H NMR (200 MHz, CDCl₃): δ = 1.40 (s, 3 H, CH₃), 1.55 (t, J = 6.9 Hz, 3 H, OCH₂CH₃), 2.84 (s, 2 H, 4'-H), 2.94–3.02 (m, 2 H, 1'-H), 3.10–3.15 (m, 2 H, 2'-H), 3.87–3.96 (m, 7 H, OCH₃, OCH₂CH₂O), 4.10 (q, J = 6.9 Hz, 2 H, OCH₂CH₃), 6.68 (d, $J_{7,5}$ = 2.5 Hz, 1 H, 7-H), 7.28 (d, $J_{5,7}$ = 2.5 Hz, 1 H, 5-H), 7.59 (s, 1 H, 4-H), 9.10 (s, 1 H, OH), 13.40 (s, 1 H, OH). – ¹³C NMR (50 MHz, CDCl₃): δ = 16.20 (q, OCH₂CH₃), 16.82 (t, C-1'), 25.05 (q, CH₃), 45.08 (t, C-2'), 51.75 (t, C-4'), 56.32 (q, OCH₃), 65.09 and 65.28 (t, OCH₂CH₂O), 70.36 (t, OCH₂CH₃), 106.80 (d, C-5), 107.61 (d, C-7), 108.17 (s), 110.39 (s), 111.39 (s), 113.55 (d, C-4), 125.37 (s), 134.70 (s), 134.79 (s), 158.85 (s), 160.13 (s), 165.59 (s, C-3 and C-8), 182.79 (s, C-10), and 186.94 (s, C-9), 212.42 (s, C-3'). – MS (EI/235°C): m/z (%) = 470 (5) [M⁺], 339 (9), 299 (10), 87 (100) [C₄H₇O₂⁺], 43 (19) [C₂H₃O⁺]. – HRMS: C₂₅H₂₆O₉: calcd.

470.157; found 470.158 \pm 3 ppm. – $C_{25}H_{26}O_9$ (470.48): calcd. C 63.82, H 5.57; found C 62.70, H 5.87.

1-Ethoxy-8-hydroxy-6-methoxy-2-[4-(2-methyl[1,3]dioxolan-2-yl)-3-oxobutyl]-3-(trifluoromethanesulfonyloxy)-9,10-anthraquinone (12): A solution of **11** (0.84 g, 1.79 mmol) in a mixture of dry CH_2Cl_2 (60 mL) and 2,6-lutidine (0.38 g, 3.58 mmol) was treated for 1 h under argon with trifluoromethanesulfonic anhydride (0.61 g, 2.15 mmol). The solution was poured into ice-cold 1 N HCl (50 mL), the aqueous phase was extracted twice with CH_2Cl_2 (30 mL) and the combined organic phases were washed with water (60 mL) and brine (60 mL), dried (Na_2SO_4), and concentrated under reduced pressure. The residue was purified by flash chromatography on silica gel to yield **12** (0.96 g, 93%) as a yellow solid; m.p. 121 °C. – IR (KBr): $\tilde{\nu}$ = 3431 cm^{-1} (OH), 2976, 2893 (CH), 1712, 1676 (C=O, quinone), 1628, 1587 (C=C, Ar). – UV (CH_2Cl_2): λ_{max} (lg ϵ) = 246 nm (4.49), 270 (4.37), 288 (4.39), 349 (3.77), 418 (3.93). – 1H NMR (200 MHz, $CDCl_3$): δ = 1.44 (s, 3 H, CH_3), 1.57 (t, J = 7.0 Hz, 3 H, OCH_2CH_3), 2.81 (s, 2 H, 4'-H), 2.87–3.14 (m, 4 H, 1'-H, 2'-H), 3.97 (s, 4 H, OCH_2CH_2O), 3.98 (s, 3 H, OCH_3), 4.13 (q, J = 7.0 Hz, 2 H, OCH_2CH_3), 6.76 (d, $J_{7,5}$ = 2.5 Hz, 1 H, 7-H), 7.35 (d, $J_{5,7}$ = 2.5 Hz, 1 H, 5-H), 8.03 (s, 1 H, 4-H), 13.06 (s, 1 H, OH). – ^{13}C NMR (50 MHz, $CDCl_3$): δ = 16.12 (q, OCH_2CH_3), 19.86 (t, C-1'), 24.90 (q, CH_3), 43.21 (t, C-2'), 52.03 (t, C-4'), 56.52 (q, OCH_3), 65.05 (t, OCH_2CH_2O), 72.42 (t, OCH_2CH_3), 107.87 and 107.96 (d, C-5 and C-7), 108.22 (s), 111.66 (s), 116.82 (d, C-4), 119.55 (s), 125.67 (s), 134.13 (s), 135.36 (s), 138.16 (s), 151.98 (s), 161.20 (s), 166.10 (s), 166.45 (s), 181.04 (s, C-9), 186.09 (s, C-10), 205.76 (s, C-3'). – MS (EI/200 °C): m/z (%) = 602 (2) [M^+], 516 (5) [M^+ – $C_4H_6O_2$], 473 (4), 339 (6), 87 (100) [$C_4H_7O_2^+$], 43 (13) [$C_2H_3O^+$]. – HRMS: $C_{26}H_{25}F_3O_{11}S$: calcd. 602.106; found 602.107 \pm 3 ppm.

Methyl 4-{4-Ethoxy-5-hydroxy-7-methoxy-3-[4-(2-methyl[1,3]dioxolan-2-yl)-3-oxobutyl]-9,10-dioxo-9,10-dihydroanthracene-2-yl}-3-methoxybut-2-enoate (14): A solution of **12** (0.86 g, 1.43 mmol), stannane **13**^[20] (1.21 g, 2.86 mmol) and the catalyst $PdCl_2(dppf)$ ^[21] (0.11 g, 10 mol-%) in dry dioxane (60 mL) was stirred under argon for 3 h at 90 °C. The mixture was then filtered through a short silica gel column (CH_2Cl_2) to remove the catalyst. The solvent was evaporated under reduced pressure and the residue was purified by chromatography on silica gel ($CH_2Cl_2/MeOH$, 99:1) to yield **14** (0.69 g, 82%) as yellow needles; m.p. 150 °C. – IR (KBr): $\tilde{\nu}$ = 3430 cm^{-1} (OH), 2978, 2944, 2896 (CH), 1712 (C=O, ester), 1672 (C=O, quinone), 1626, 1586 (C=C, Ar). – UV (CH_2Cl_2): λ_{max} (lg ϵ) = 232 nm (4.60), 270 (4.46), 412 (3.97). – 1H NMR (200 MHz, $CDCl_3$): δ = 1.45 (s, 3 H, CH_3), 1.54 (t, J = 6.9 Hz, 3 H, OCH_2CH_3), 2.80 (s, 2 H, 4''-H), 2.82–3.06 (m, 4 H, 1''-H, 2''-H), 3.68 (s, 3 H, OCH_3), 3.71 (s, 3 H, OCH_3), 3.93 (s, 3 H, OCH_3), 3.97 (s, 4 H, OCH_2CH_2O), 4.05 (q, J = 6.9 Hz, 2 H, OCH_2CH_3), 4.34 (s, 2 H, 4-H), 5.27 (s, 1 H, 2-H), 6.70 (d, $J_{6',8'}$ = 2.4 Hz, 1 H, 6'-H), 7.29 (d, $J_{8',6'}$ = 2.4 Hz, 1 H, 8'-H), 7.86 (s, 1 H, 1'-H), 13.30 (s, 1 H, OH). – ^{13}C NMR (50 MHz, $CDCl_3$): δ = 16.17 (q, OCH_2CH_3), 21.60 (t, C-1''), 24.86 (q, CH_3), 35.73 (t, C-4), 43.88 (t, C-2''), 51.53 (q, CO_2CH_3), 52.03 (t, C-4''), 56.31 (q, OCH_3), 56.33 (q, OCH_3), 65.02 (t, OCH_2CH_2O), 71.28 (t, OCH_2CH_3), 93.06 (d, C-2), 107.01 and 107.40 (d, C-6' and C-8'), 108.24 (s), 111.93 (s), 124.02 (s), 125.09 (d, C-1'), 133.48 (s), 134.77 (s), 144.00 (s), 144.86 (s), 159.03 (s), 165.75 (s), 165.99 (s), 168.09 (s, C-1), 172.06 (s, C-3), 182.80 (s, C-9'), 187.55 (s, C-10'), 206.79 (s, C-3''). – MS (EI/180 °C): m/z (%) = 582 (14) [M^+], 87 (100) [$C_4H_7O_2^+$]. – HRMS: $C_{31}H_{34}O_{11}$: calcd. 582.210; found 582.210 \pm 3 ppm. – $C_{31}H_{34}O_{11}$ (582.60): calcd. C 63.91, H 6.37; found C 63.34, H 5.88.

Methyl 4-[3-(3,5-Dioxohexyl)-4-ethoxy-5-hydroxy-7-methoxy-9,10-dioxo-9,10-dihydroanthracene-2-yl]-3-oxobutanoate (15): A solution

of **14** (0.20 g, 0.34 mmol) in a mixture of THF (10 mL) and 1 N HCl (5 mL) was heated under reflux for 3 h. The solution was diluted with water (15 mL) and extracted three times with CH_2Cl_2 (15 mL). The combined organic phases were washed with water (10 mL), dried (Na_2SO_4), filtered, and concentrated under reduced pressure. The residue was purified by chromatography ($CH_2Cl_2/MeOH$, 99:1) to afford **15** (0.17 g, 95%) as a yellow solid; m.p. 179 °C. – The NMR spectra showed that the 1,3-dione **15** was almost completely enolized in $CDCl_3$ solution. – IR (KBr): $\tilde{\nu}$ = 3429 cm^{-1} (OH), 2981 (CH), 1746, 1714 (C=O, ester), 1627 (C=O, quinone), 1578 (C=C, Ar). – UV (CH_2Cl_2): λ_{max} (lg ϵ) = 229 nm (4.50), 272 (4.66), 415 (4.06). – 1H NMR (200 MHz, $CDCl_3$): δ = 1.58 (t, J = 6.8 Hz, 3 H, OCH_2CH_3), 2.05 (s, 3 H, CH_3), 2.59–2.66 (m, 2 H, 1''-H), 2.89–2.99 (m, 2 H, 2''-H), 3.66 (s, 2 H, 2-H), 3.81 (s, 3 H, OCH_3), 3.95 (s, 3 H, OCH_3), 4.11 (q, J = 6.8 Hz, 2 H, OCH_2CH_3), 4.20 (s, 2 H, 4-H), 5.49 (s, 1 H, 4''-H), 6.73 (d, $J_{6',8'}$ = 1.9 Hz, 1 H, 6'-H), 7.32 (d, $J_{8',6'}$ = 1.9 Hz, 1 H, 8'-H), 7.87 (s, 1 H, 1'-H), 13.25 (s, 1 H, OH), 15.34 (s, 1 H, OH). – ^{13}C NMR (50 MHz, $CDCl_3$): δ = 16.27 (q, OCH_2CH_3), 23.98 (t, C-1''), 24.80 (q, CH_3), 38.31 (t, C-2''), 48.53 and 49.20 (t, C-2 and C-4), 53.05 (q, CO_2CH_3), 56.40 (q, OCH_3), 71.43 (t, OCH_2CH_3), 100.45 (d, C-4''), 107.18 and 107.60 (d, C-6' and C-8'), 111.93 (s), 124.77 (s), 126.71 (d, C-1'), 133.78 (s), 134.64 (s), 140.84 (s), 144.02 (s), 159.45 (s), 165.82 and 166.15 (s, C-5' and C-7'), 167.59 (s, C-1), 182.54 (s, C-9'), 187.36 (s, C-10'), 190.11 and 194.32 (s, C-3'' and C-5''), 199.14 (s, C-3). – MS (EI/170 °C): m/z (%) = 524 (34) [M^+], 466 (100) [M^+ – $C_3H_6O^+$], 378 (77), 337 (56), 309 (45), 297 (33), 85 (32), 43 (90) [$C_2H_3O^+$], 31 (57) [CH_3O^+]. – HRMS: $C_{28}H_{28}O_{10}$: calcd. 524.168; found 524.167 \pm 3 ppm. – $C_{28}H_{28}O_{10}$ (524.52): calcd. C 64.12, H 5.38; found C 64.16, H 5.35.

Methyl 1,9-Bis(2,2-dimethylpropionyloxy)-7-ethoxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenz[a]naphthacene-2-carboxylate (17): A solution of **15** (62 mg, 0.12 mmol) in a mixture of 2-propanol (4 mL) and CH_2Cl_2 (4 mL) was treated with powdered K_2CO_3 (163 mg, 1.20 mmol) and the suspension was stirred for 5 h at 45 °C (TLC monitoring). The mixture was acidified by addition of 1 N HCl, extracted three times with CH_2Cl_2 (20 mL) and concentrated under reduced pressure to yield crude methyl 7-ethoxy-1,9-dihydroxy-11-methoxy-3-methyl-8,13-dioxo-5,6,8,13-tetrahydrobenz[a]naphthacene-2-carboxylate (**16**) (60 mg, quantitative). Part of this solid (15 mg, 0.03 mmol) was converted into the dipivaloate for characterization as described above for **7** to yield **17** (15 mg, 74%) as a yellow solid; m.p. 68–70 °C. – IR (KBr): $\tilde{\nu}$ = 2973 cm^{-1} , 2931 (CH), 1758, 1734 (C=O, ester), 1673 (C=O, quinone), 1603, 1581 (C=C, Ar). – UV (CH_2Cl_2): λ_{max} (lg ϵ) = 230 nm (4.59), 297 (4.76), 374 (3.88). – 1H NMR (200 MHz, $CDCl_3$): δ = 1.32 [s, 9 H, $C(CH_3)_3$], 1.53 (t, J = 6.8 Hz, 3 H, OCH_2CH_3), 1.53 [s, 9 H, $C(CH_3)_3$], 2.41 (s, 3 H, CH_3), 2.75–2.82 (m, 2 H, -H), 3.02 (br. s, 2 H, -H), 3.95 (s, 3 H, OCH_3), 3.99 (s, 3 H, OCH_3), 4.03 (q, J = 6.8 Hz, 2 H, OCH_2CH_3), 6.86 (d, $J_{10,11}$ = 2.7 Hz, 1 H, 10-H), 7.10 (s, 1 H, 4-H), 7.68 (d, $J_{11,12}$ = 2.7 Hz, 1 H, 12-H), 8.58 (s, 1 H, 14-H). – ^{13}C NMR (50 MHz, $CDCl_3$): δ = 16.02 (q, OCH_2CH_3), 20.22 (q, CH_3), 22.18 (t), 27.54 and 27.71 [q, $C(CH_3)_3$], 29.31 (t), 39.63 [s, $2 \times C(CH_3)_3$], 52.80 (q, CO_2CH_3), 56.57 (q, OCH_3), 70.91 (t, OCH_2CH_3), 109.08 (d, C-12), 116.57 (d, C-10), 121.24 (s), 122.29 (d, C-14), 125.64 (s), 126.33 (s), 127.48 (s), 128.01 (d, C-4), 132.67 (s), 136.47 (s), 137.86 (s), 138.06 (s), 141.46 (s), 142.56 (s), 146.12 (s), 152.56 (s), 156.52 (s), 163.90 (s), 167.60 (s, CO_2CH_3), 176.72 and 177.15 (s, CO_2Piv), 181.07 and 182.94 (s, C-8 and C-13). – MS (EI/200 °C): m/z (%) = 656 (15) [M^+], 571 (43) [M^+ – C_5H_9O], 487 (68), 454 (35), 427 (14), 57 (100) [$C_3H_5O^+$]. – HRMS: $C_{38}H_{40}O_{10}$: calcd. 656.262; found 656.262 \pm 3 ppm.

G-2A (1) and G-2N (2): A mixture of AlCl_3 (2.50 g, 18.75 mmol) and NaCl (0.50 g, 8.56 mmol) was heated under argon to 150°C . Compound **16** (40 mg, 0.08 mmol, obtained from the cyclization of **15**, see above) was then added in one portion. The melt was hydrolyzed after 5 min at 150°C by addition of a mixture of ice (100 g) and conc. HCl (10 mL). The suspension was stirred for 30 min at 20°C , and then for 5 min at 50°C . The suspension was filtered to yield **1**^[1] as an almost insoluble violet powder (31 mg, 87%). – MS (DCI/NH_3): m/z (%) = 432 (0.5) [M^+], 388 (73) [$\text{M}^+ - \text{CO}_2$], 148 (100). – HRMS: $\text{C}_{23}\text{H}_{16}\text{O}_6$: calcd. 388.094; found 388.094 ± 3 ppm. – Decarboxylation of the acid **1** (10 mg) was performed as described in the literature^[14] to yield G-2N (**2**) (6 mg, 69%).

Acknowledgments

We thank the Deutsche Forschungsgemeinschaft for financial support of this work

- [1] N. N. Gerber, M. P. Lechevalier, *Can. J. Chem.* **1984**, *62*, 2818–2821.
 [2] F. M. Hauser, Y. Caringal, *J. Org. Chem.* **1990**, *55*, 555–559.
 [3] E. F. Paulus, K. Dornberger, W. Werner, D. Fenske, *Acta. Crystallogr.* **1994**, *C50*, 2064–2067.
 [4] T. Oki, M. Konishi, K. Tomatsu, K. Tomita, K. I. Saitoh, M. Tsunakawa, M. Nishio, T. Miyaki, H. Kawaguchi, *J. Antibiot.* **1988**, *41*, 1701–1704.
 [5] K. Tomita, M. Nishio, K. Saitoh, H. Yamamoto, Y. Hoshino, H. Ohkuma, M. Konishi, T. Miyaki, T. Oki, *J. Antibiot.* **1990**, *43*, 755–762.
 [6] T. Takeuchi, T. Hara, H. Naganawa, M. Okada, H. Umezawa, *J. Antibiot.* **1988**, *41*, 807–811.
 [7] S. Kondo, S. Gomi, D. Ikeda, M. Hamada, T. Takeuchi, H. Iwai, J. Seki, H. Hoshino, *J. Antibiot.* **1991**, *44*, 1228–1236.
 [8] T. Oki, M. Kakushima, M. Hirano, A. Takahashi, A. Ohta, S. Masuyoshi, M. Hatori, H. Kamei, *J. Antibiot.* **1992**, *45*, 1512–1517.
 [9] S. F. Queener, *J. Med. Chem.* **1995**, *38*, 4739–4759.
 [10] G. Kraus, G. Zhao, *J. Org. Chem.* **1996**, *61*, 2770–2773.
 [11] S. Hirosawa, T. Nishizuka, S. Kondo, D. Ikeda, T. Tekeuchi, *J. Antibiot.* **1997**, *50*, 685–688.
 [12] T. Nishizuka, S. Hirosawa, S. Kondo, D. Ikeda, T. Tekeuchi, *J. Antibiot.* **1997**, *50*, 755–769.
 [13] S. Hirosawa, T. Nishizuka, S. Kondo, D. Ikeda, *Chem. Lett.* **1997**, 305–306.
 [14] T. R. Kelly, W. Xu, Z. Ma, Q. Li, V. Bushan, *J. Am. Chem. Soc.* **1993**, *115*, 5843–5844.
 [15] K. Krohn, N. Böker, U. Flörke, C. Freund, *J. Org. Chem.* **1997**, *62*, 2350–2356.
 [16] T. M. Harris, C. M. Harris, K. B. Hindley, *Fortschr. Chem. Org. Naturstoff.* **1974**, *31*, 217–282.
 [17] J. Savard, P. Brassard, *Tetrahedron* **1984**, *40*, 3455–3464.
 [18] G. A. Molander, K. O. Cameron, *J. Am. Chem. Soc.* **1993**, *115*, 830–846.
 [19] K. Krohn, N. Böker, *J. Prakt. Chem.* **1997**, 114–120.
 [20] K. Krohn, C. Freund, U. Flörke, *Eur. J. Org. Chem.* **1998**, 2713–2718.
 [21] T. Hayashi, M. Konishi, Y. Kobori, M. Kumada, T. Higuchi, K. Hirotsu, *J. Am. Chem. Soc.* **1984**, *106*, 158–163.
 [22] D. W. Cameron, D. J. Deutscher, G. I. Feutrill, P. G. Griffith, *Aust. J. Chem.* **1981**, *34*, 2401–2421.
 [23] K. Krohn, A. Michel, U. Flörke, H.-J. Aust, S. Draeger, B. Schulz, *Liebigs Ann. Chem.* **1994**, 1093–1097.
 [24] L. Boisvert, P. Brassard, *Chem. Lett.* **1989**, 1055–1058.
 [25] K. Krohn, N. Böker, A. Gohier, G. Schäfer, F. Werner, *J. Prakt. Chem.* **1996**, *338*, 349–354.

Received April 21, 1999
 [O99230]